HAE · All filings · Read this filing
What changed 10-Q
Item 1A. Risk Factors
2021-02-02 compared with 2020-11-04 · 3 added, 2 removed, 7 unchanged (42% of the section changed)
2 unchanged sentences
In May 2019, our Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the next two years.
−Removed: We had no share repurchases during the six months ended September 26, 2020.
−Removed: The total remaining authorization for repurchases of our common stock under the share repurchase program was $325 million as of September 26, 2020.
+Added: We had no share repurchases during the nine months ended December 26, 2020.
+Added: The total remaining authorization for repurchases of our common stock under the share repurchase program was $325 million as of December 26, 2020.
+Added: We do not expect to make additional share repurchases prior to the expiration of the share repurchase program in May 2021.
Defaults Upon Senior Securities
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.